A compound having the structure of Formula: wherein: is; each R 1 is independently selected from C 2-6 alkynyl, C 1-6 alkyl-OR 7, C 3-8 cycloalkyl, -NR 5 R 6, OR 7, -SO 2 R 12, -SF 5, -SR 8, aryl, and heteroaryl, wherein aryl and heteroaryl are substituted with one or two groups independently selected from -C NR 8 R 9; or two adjacent R 1 form a heterocycloalkyl ring optionally substituted with one or two R 11; R 2 is C 1-6 alkyl; R 3 is selected from halogen, -CN, C 1-6 alkyl, C 1-6 haloalkyl, -NR 8 R 9, -C NR 8 R 9, -NR 8 C R 9, and -NR 9 SO 2 R 8; R 3a is selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 4 is independently selected from H and C 1-6 alkyl; each R 5 and R 6 is independently selected from H, C 1-6 alkyl, and C 3-8 cycloalkyl; or R 5 and R 6, together with the nitrogen to which they are attached, form a heterocycloalkyl optionally substituted with one or two R 10; each R 7 is independently selected from H, C 1-6 alkyl-O-C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one or two groups independently selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 8 and R 9 is independently selected from H, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and heteroaryl; each R 10 is independently selected from C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, halogen, oxo, -CN, -C OR 8, -C R 8, -C NR 8 R 9, -SO 2 R 8, -NR 9 C R 8, and -NR 9 SO 2 R 8; each R 11 is independently selected from halogen and C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl and C 3-8 cycloalkyl; m is 1, 2, 3, 4, or 5; p is 1; and q is 0 or 1; or a pharmaceutically acceptable salt, solvate, isotopically-labeled form or stereoisomer thereof. each R 1 is independently selected from C 2-6 alkynyl, C 1-6 alkyl-OR 7, C 3-8 cycloalkyl, -NR 5 R 6, OR 7, -SO 2 R 12, -SF 5, -SR 8, aryl, and heteroaryl, wherein aryl and heteroaryl are substituted with one or two groups independently selected from -C NR 8 R 9; or two adjacent R 1 form a heterocycloalkyl ring optionally substituted with one or two R 11; R 2 is C 1-6 alkyl; R 3 is selected from halogen, -CN, C 1-6 alkyl, C 1-6 haloalkyl, -NR 8 R 9, -C NR 8 R 9, -NR 8 C R 9, and -NR 9 SO 2 R 8; R 3a is selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 4 is independently selected from H and C 1-6 alkyl; each R 5 and R 6 is independently selected from H, C 1-6 alkyl, and C 3-8 cycloalkyl; or R 5 and R 6, together with the nitrogen to which they are attached, form a heterocycloalkyl optionally substituted with one or two R 10; each R 7 is independently selected from H, C 1-6 alkyl-O-C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one or two groups independently selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 8 and R 9 is independently selected from H, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and heteroaryl; each R 10 is independently selected from C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, halogen, oxo, -CN, -C OR 8, -C R 8, -C NR 8 R 9, -SO 2 R 8, -NR 9 C R 8, and -NR 9 SO 2 R 8; each R 11 is independently selected from halogen and C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl and C 3-8 cycloalkyl; m is 1, 2, 3, 4, or 5; p is 1; and q is 0 or 1; or a pharmaceutically acceptable salt, solvate, isotopically-labeled form or stereoisomer thereof.